PF-06687234 + infliximab

PF-06687234 + infliximab is a **combination therapy** investigated for the treatment of **active ulcerative colitis** in patients who experience a partial response to anti-TNF-α therapy[1][3][6]. PF-06687234 is an investigational biologic with an undisclosed detailed mechanism of action, developed to act as an add-on to infliximab, a licensed monoclonal antibody against tumor necrosis factor alpha (TNF-α). Clinical studies focused on efficacy (remission rates, endoscopic improvement), safety, tolerability, pharmacokinetics, and immunogenicity[1][2][3][6]. The phase IIa trial did not show a significant difference in clinical remission between the combination and placebo + infliximab arms. PF-06687234 was discontinued for further development for ulcerative colitis[3].

Other names

PF-06687234 plus infliximabPF06687234 plus infliximabPF 06687234 plus infliximab